Todos Medical

Company Overview

Snapshot

Founded in November 2009, Todos Medical operates with 1–10 employees. The company has raised $3.45 million across 4 funding rounds from 2 investors. In April 2021, Todos Medical acquired Provista Diagnostics, expanding its diagnostic capabilities.

Business overview

Todos Medical engineers diagnostic solutions for the early detection of various cancers and neurodegenerative disorders like Alzheimer's disease. The company's core technology, Todos Biochemical Infrared Analyses, utilizes peripheral blood analysis to identify biochemical changes in immune system cells and plasma indicative of cancer. Operating within the Health Tech & Life Sciences sector, Todos Medical serves the medical technologies and diagnostics industries with products such as TMB-1, TMB-2, and LymPro, which have received CE mark in Europe.

Strategic signal

In September 2023, Todos Medical announced a corporate retooling to focus on the Long COVID epidemic. This strategic pivot indicates the company's agility in responding to emerging health crises and adapting its diagnostic and therapeutic development efforts to address significant unmet medical needs, signaling a potential shift in market focus for investors.

Company Intelligence Q&A

What was a significant strategic acquisition made by Todos Medical?

In April 2021, Todos Medical acquired.

What was a key development regarding Todos Medical's intellectual property in 2022?

In September 2022, Todos Medical received two Notices of Allowance from the USPTO for its AI-Based TBIA Pan-Cancer Blood Diagnostics Platform, strengthening its patent position in advanced diagnostic technologies.

What was Todos Medical's strategic focus shift announced in September 2023?

In September 2023, Todos Medical announced a corporate retooling to focus on the Long COVID epidemic, indicating a strategic shift towards addressing this emerging health challenge.

When did Todos Medical become a publicly traded company?

Todos Medical became public on OTCBB in February 2016.

What was a notable partnership for Todos Medical in the COVID-19 testing space?

In March 2020, Todos Medical signed an exclusive distribution agreement with Shanghai Liangrun Subsidiary Gibraltar for novel coronavirus (COVID-19) point-of-care rapid antibody testing kits in the United States and Israel.